| Symbol | ALXO |
|---|---|
| Name | ALX ONCOLOGY HOLDINGS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA 94080 |
| Telephone | 650-466-7125 |
| Fax | — |
| — | |
| Website | https://www.alxoncology.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001810182 |
| Description | ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a dont eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Additional info from NASDAQ: |
Wong Shelly 🔴 sold 1.4K shares of ALX ONCOLOGY HOLDINGS INC (ALXO) at $2.04 Transaction Date: Jul 01, 2026 | Filing ID: 296246
Read moreALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Read moreALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Read more(99% Neutral) ALX ONCOLOGY HOLDINGS INC (ALXO) Announces Regulatory Update
Read moreNew Form SCHEDULE 13D/A - ALX ONCOLOGY HOLDINGS INC <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 0001643828-26-000002 <b>Size:</b> 18 KB
Read moreNew Form SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062566 <b>Size:</b> 13 KB
Read moreNew Form SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062512 <b>Size:</b> 7 KB
Read moreALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
Read moreNew Form SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050505 <b>Size:</b> 18 KB
Read more